Tuesday, 15 Oct 2019

You are here

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

A longitudinal health administrative data (HAD) study from British Columbia, Canada compared two cohorts of 7,743 OA patients and 23,229 non‐OA controls to examin the risk of incident CVD (primary outcome) as well as ischemic heart disease (IHD), congestive heart failure (CHF) and stroke (secondary outcomes).

OA patients had a higher risk of developing CVD compared to people without OA. The adjusted hazard ration (HR) was 1.23 (95% CI, 1.17, 1.28) and was 1.42, 1.17, and 1.14 for CHF, IHD and stroke, respectively.

Approximately 41% of the total effect of OA on increased CVD risk was mediated through NSAID.

These data show an increased risk of CVD in OA patients and is the first study to show that NSAID's substantially mediated this risk.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hydroxychloroquine Blood Levels May Predict Future Retinopathy

A study of 527 patients receiving daily hydroxychloroquine (HCQ) concluded that hydroxychloroquine blood levels may predict future HCQ retinopathy.

This study assessed whether lower HCQ dosing, as recommended by the 2016 American Academy of Ophthalmology (AAO) guidelines (less than 5 mg/kg), would favorably affect retinopathy outcomes.

Arthritis Foundation Releases First CBD Guidance for Adults With Arthritis

As the leading organization for people with arthritis, the Arthritis Foundation has just released the first CBD guidance for adults with arthritis. CBD, or cannabidiol, a plant-based compound, has become popular among people with arthritis seeking to ease chronic joint pain.

Persistent Inflammatory Arthritis After Immune Checkpoint Inhibitors

Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies, showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis.